ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

Summary

This study will investigate the efficacy of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and whose esophageal or esophagogastric junction (EGJ) cancer expresses the MAGE-A4 protein.

Timeline

Start

2021-09-15

Primary completion

2023-06-09

Completion

2023-12-15

Outcome

Outcome not reported

Stopped (Enrollment): “Study was terminated due to difficulty recruiting subjects and lack of efficacy”

Drugs

Indications